Hercules Capital Inc - HTGC STOCK NEWS

Hercules Capital, Inc. (NYSE: HTGC) announced that Kroll Bond Rating Agency reaffirmed its investment grade corporate and credit rating at BBB+ with a stable outlook. This rating underscores Hercules' effective venture capital lending strategy and the strong management team's capabilities. The rating reflects the company's focus on senior secured debt investments in technology and life sciences, minimal non-accruals, and solid capital market access. Since its inception, Hercules has committed over $15 billion to more than 590 companies, establishing itself as a leading finance provider.

Provention Bio (Nasdaq: PRVB) announced a term loan facility worth up to $125 million with Hercules Capital (NYSE: HTGC) to bolster its financial standing ahead of the potential commercial launch of teplizumab. The loan is structured in five tranches, with an initial draw of $25 million at closing and the possibility of further disbursements contingent on FDA approval and achievement of specific milestones. This financing aims to enhance the development of therapies for type 1 diabetes and improve the lives of affected individuals.

Hercules Capital (NYSE: HTGC) reported record financial metrics for the first half of 2022, including total gross debt and equity commitments of $1.66 billion and gross fundings of $790.7 million. The net debt investment portfolio grew by $359.8 million. For Q2, total gross debt and equity commitments reached $1.04 billion, and the quarterly base cash distribution increased to $0.35 per share. The company also announced an undistributed earnings spillover of $150.5 million.

IVERIC bio, Inc. (Nasdaq: ISEE) has secured a $250 million term loan debt financing facility from Hercules Capital (NYSE: HTGC) and Silicon Valley Bank. This non-dilutive financing strengthens the company's balance sheet, allowing it to fund the potential launch of Zimura® (avacincaptad pegol) in the U.S., pending regulatory approval. The initial $50 million will be drawn in July 2022, with additional funds contingent on achieving performance milestones. Iveric plans to report data from the GATHER2 clinical trial in September 2022, crucial for Zimura's development.

Hercules Capital, Inc. (NYSE: HTGC) announced a supplemental cash distribution of $0.15 per share, in addition to its regular quarterly distribution of $0.35 for Q2 2022. The supplemental distribution, to be paid from undistributed taxable income, has a record date of August 9, 2022 and a payment date of August 16, 2022. Hercules aims to distribute 90%-100% of its taxable income quarterly and has designated 87.1% of this distribution as Qualified Interest Income, potentially exempting it from U.S. withholding tax for foreign shareholders.

Hercules Capital, the leading specialty finance provider, announced a second quarter 2022 cash distribution of $0.35 per share. The record date is August 9, 2022, with payments made on August 16, 2022. The company's distribution policy aims to allocate approximately 90% to 100% of its taxable income. For the second quarter, 87.1% of the declared distributions were from current and accumulated earnings. Hercules has committed over $14 billion to more than 570 companies since its inception in December 2003.

Hercules Capital, Inc. (NYSE: HTGC) has announced a conference call scheduled for July 28, 2022, at 2:00 p.m. PT to discuss its second quarter 2022 financial results. The results will be released after market close the same day. Hercules Capital, a leader in providing senior secured loans to venture-backed companies, has committed over $14 billion to more than 570 companies since its inception in 2003. Investors can participate through a live webcast or via telephone registration.

Geron Corporation announces an expansion of its loan facility with Hercules Capital and Silicon Valley Bank, increasing access from $75 million to $125 million. This amendment allows for an additional $50 million in potential non-dilutive capital in 2023, crucial for the company as it anticipates top-line results from the Phase 3 IMerge trial in January 2023. Funding aims to support operations and potential commercialization of imetelstat until mid-2024.

Hercules Capital (NYSE: HTGC) announced the appointment of DeAnne Aguirre as an independent board member, effective June 23, 2022. With over 30 years of executive experience in managing complex business units, Aguirre will join the Nominating and Corporate Governance Committee. CEO Scott Bluestein highlighted her extensive industry experience as a valuable asset for the firm, especially as it expands its market reach. Aguirre's previous roles include being Managing Partner at PricewaterhouseCoopers and serving on the board of Cisive.